

JUL 28 2005 11:23AM AVENTIS US PAT DEPT  
TO: US CENTRALIZED USPTO

RECEIVED  
CENTRAL FAX CENTER

JUL 28 2005

NO. 7151 P. 1/3

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

3

Application Number

10/774,721

Filing Date

February 09, 2004

First Named Inventor

Ralf JOCKERS et al.

Art Unit

1635

Examiner Name

WOLLENBERGER, Louis V.

Attorney Docket Number

FRAV2003/0005 US NP

### ENCLOSURES (Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)



Reply to Missing Parts/  
Incomplete Application



Reply to Missing Parts  
under 37 CFR 1.52 or 1.53



Drawing(s)



Licensing-related Papers



Petition



Petition to Convert to a  
Provisional Application



Power of Attorney, Revocation



Change of Correspondence Address



Terminal Disclaimer



Request for Refund



CD, Number of CD(s) \_\_\_\_\_



Landscape Table on CD

Remarks



After Allowance Communication to TC



Appeal Communication to Board  
of Appeals and Interferences



Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)



Proprietary Information



Status Letter



Other Enclosure(s) (please identify  
below):

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

sanofi-aventis

Signature

*Karen Krupen*

Printed name

Karen I. Krupen

Date

July 28, 2005

Reg. No.

34,647

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571 273-8300 ; Total No. of Pages Transmitted: 3 )

Signature

*Delia Coughlin*

Typed or printed name

Delia Coughlin

Date

7/28/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**JOCKERS et al.**

Examiner: Wollenberger, Louis

Art Unit: 1635

**RECEIVED**  
CENTRAL FAX CENTER

Application No.: 10/774,721

**JUL 28 2005**

Filed: February 9, 2003

**Title: OLIGONUCLEOTIDES WHICH INHIBIT  
EXPRESSION OF THE OB-RGRP PROTEIN AND  
METHOD FOR DETECTING COMPOUNDS  
WHICH MODIFY THE INTERACTION  
BETWEEN PROTEINS OF THE OB-RGRP  
FAMILY AND THE LEPTIN RECEPTOR**

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is  
being transmitted via facsimile to the  
Commissioner for Patents, Alexandria,  
VA 22313, on

Date of transmission

Signature


**RESPONSE TO OFFICE COMMUNICATION**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sirs:

In response to the Office Action dated June 15, 2005 in connection with the above-identified application, Applicants elect to prosecute the claims of Group II (claims 12-17 and 42-44) and further elect the species SEQ ID NO: 37.

Respectfully submitted,

  
\_\_\_\_\_  
Karen I. Krupen, Reg. No. 34,647

Attorney for Applicants

sanofi-aventis  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626  
Aventis Docket No. FRAV2003/0005 US NP